India Pharma Outlook Team | Wednesday, 26 August 2026
Researchers at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) have developed a smartphone-based tool for Alzheimer’s detection.
The platform, called ADxFluo, detects amyloid-β (Aβ), a key biomarker linked to Alzheimer’s disease. It uses a fluorescence-responsive molecule called TZ-48 to identify changes in the biomarker.
A smartphone application then measures the resulting fluorescence signal. Researchers found that ADxFluo could detect Aβ in blood serum and cerebrospinal fluid.
The technology could support earlier Alzheimer’s screening and disease staging. It may also offer a faster and more cost-effective approach to detection.
The new approach focuses on amyloid-β, a biomarker closely associated with Alzheimer’s disease. Researchers designed TZ-48 to respond to Aβ by changing its fluorescence intensity. The smartphone application then captures these changes and quantifies the signal, creating a digital route for measuring the biomarker.
The research team included Krithi K. Bhagavath, Madhu Ramesh, Yogendra Kumar, Sabyasachi Mandal, Hiriyakkanavar Ila and Thimmaiah Govindaraju. The team published the research in ACS Chemical Neuroscience.
According to the Department of Science and Technology, TZ-48 also demonstrated blood-brain barrier permeability, labeled Aβ plaques in transgenic Alzheimer’s disease mouse brains, and worked with confocal laser scanning microscopy and fluorescence lifetime imaging microscopy. Researchers also detected Aβ in cerebrospinal fluid and blood serum during the study.
Also Read: Building Resilient QMS in Global Pharma Manufacturing
The researchers developed ADxFluo to move beyond laboratory-based biomarker analysis. The platform combines biofluid detection, fluorescence measurement and smartphone-based quantification in one system. This design could support portable and user-friendly diagnostic workflows if further research establishes its clinical performance.
The Department of Science and Technology describes ADxFluo as a potential low-cost, point-of-care diagnostic system for Alzheimer’s disease. The platform could therefore create another route for Alzheimer’s screening, particularly where access to sophisticated diagnostic infrastructure remains limited.
The development also comes as researchers explore other ways to use smartphones for earlier Alzheimer’s detection. A 2026 study from researchers at the University of Wisconsin–Madison and partner institutions found that smartphone- and tablet-based memory tests could identify subtle memory decline. That work involved about 200 older adults and suggested that digital testing could capture changes that conventional assessments may miss.
However, the JNCASR platform currently represents a research-stage technology, rather than a smartphone-based diagnostic that people can independently use to confirm Alzheimer’s disease. Its significance lies in combining a disease-related biomarker with portable digital quantification. Further validation will determine how effectively the approach can translate into clinical Alzheimer’s screening.
.jpg)
